Claims
- 1. A compound of the formula ##STR18## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, carboxyl, C.sub.2-6 alkoxycarbonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylamino-C.sub.1-4 alkylcarbamoyl, N-C.sub.1-4 alkylpyrrolidinyl-C.sub.1-4 alkylcarbamoyl, ureido, C.sub.1-4 alkylureido, thioureido, C.sub.1-4 alkylthioureido, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4 alkylsulfonyl, aminomethyl, mono- or di-C.sub.1-4 alkylaminomethyl, cyano, phenyl, amino, mono- or bis-(.beta.-hydroxyethyl)amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atom of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or
- two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring.
- 2. A compound of the formula ##STR19## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atom of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or
- two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring.
- 3. A compound according to claim 2, wherein R.sup.1 is di-C.sub.1-4 alkylamino and R.sup.2, R.sup.3 and R.sup.4 are hydrogen.
- 4. A compound according to claim 2, wherein R.sup.1 is C.sub.2-6 alkanoyl and R.sup.2, R.sup.3 and R.sup.4 are hydrogen.
- 5. The compound according to claim 2, which is spiro[benzo[b]furan-2-(3H),1'-cyclopropane]-3-one.
- 6. The compound according to claim 2, which is spiro[naphtho[2,3-b]furan-2(3H),1'-cyclopropane]-3-one.
- 7. The compound according to claim 2, which is 5-nitrospiro[benzo[b]furan-2-(3H),1'-cyclopropane]-3-one.
- 8. The compound according to claim 2, which is 5-aminospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 9. The compound according to claim 2, which is 5-methylaminospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 10. A compound of the formula ##STR20## wherein R.sup.1' is di-C.sub.1-4 alkylamino, or a pharmaceutically acceptable salt thereof.
- 11. The compound according to claim 10, which is 5-dimethylaminospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 12. The compound according to claim 10, which is 5-diethylaminospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 13. A compound of the formula ##STR21## wherein R.sup.1" is C.sub.2-6 alkanoyl.
- 14. The compound according to claim 13, which is 5-acetylspiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 15. A pharmaceutical composition for managing peptic ulcer which comprises, as an active ingredient, an effective amount of a compound of the formula ##STR22## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, carboxyl, C.sub.2-6 alkoxycarbonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylamino-C.sub.1-4 alkylcarbamoyl, N-C.sub.1-4 alkylpyrrolidinyl-C.sub.1-4 alkylcarbamoyl, ureido, C.sub.1-4 alkylureido, thioureido, C.sub.1-4 alkylthioureido, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4 alkylsulfonyl, aminomethyl, mono- or di-C.sub.1-4 alkylaminomethyl, cyano, phenyl, amino, mono- or bis-(.beta.-hydroxyethyl)amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atom of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or
- two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring, and a pharmaceutically acceptable carrier or diluent therefor.
- 16. A pharmaceutical composition for managing peptic ulcer which comprises, as an active ingredient, an effective amount of a compound of the formula ##STR23## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atom of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or
- two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring and a pharmaceutically acceptable carrier or diluent therefor.
- 17. A method of managing peptic ulcer in a patient which comprises administering to said patient a compound of the formula ##STR24## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, carboxyl, C.sub.2-6 alkoxycarbonyl, carbamoyl, C.sub.1-4 alkylcarbamoyl, di-C.sub.1-4 alkylamino-C.sub.1-4 alkylcarbamoyl, N-C.sub.1-4 alkylpyrrolidinyl-C.sub.1-4 alkylcarbamoyl, ureido, C.sub.1-4 alkylureido, thioureido, C.sub.1-4 alkylthioureido, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4 alkylsulfonyl, aminomethyl, mono- or di-C.sub.1-4 alkylaminomethyl, cyano, phenyl, amino, mono- or bis-(.beta.-hydroxyethyl)amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atoms of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or
- two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring.
- said compound being administered in an amount effective to manage peptic ulcer in said patient.
- 18. A method of managing peptic ulcer in a patient which comprises administering to said patient a compound of the formula ##STR25## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently hydrogen, C.sub.1-6 alkyl, nitro, halogen, hydroxyl, C.sub.1-6 alkoxy, mono- or di-C.sub.1-4 alkylamino-C.sub.1-6 alkoxy, phenyl-C.sub.1-4 alkyloxy, C.sub.2-6 alkanoyloxy, benzoyloxy, C.sub.2-6 alkanoyl, benzoyl, sulfamoyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.2-4 alkanoylamino, C.sub.1-4 alkanesulfonylamino, 1-pyrrolidinyl, piperidino, a 1-piperazinyl group, or morpholino, said 1-piperazinyl group being unsubstituted or substituted at the nitrogen atom of its 4-position by C.sub.1-4 alkyl, phenyl-C.sub.1-4 alkyl or C.sub.2-4 alkanoyl, or
- two of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 together form --CH.dbd.CH--CH.dbd.CH-- at adjacent carbon atoms of the benzene ring,
- said compound being administered in an amount effective to manage peptic ulcer in said patient.
- 19. A method according to claim 18, wherein R.sup.1 is di-C.sub.1-4 alkylamino and R.sup.2, R.sup.3 and R.sup.4 are hydrogen.
- 20. A method according to claim 18, wherein R.sup.1 is C.sub.2-6 alkanoyl and R.sup.2, R.sup.3 and R.sup.4 are hydrogen.
- 21. The method according to claim 18, wherein the compound is spiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 22. The method according to claim 18, wherein the compound is spiro[naphtho[2,3-b]furan-2(3H),1'-cyclopropane]-3-one.
- 23. The method according to claim 18, wherein the compound is 5-nitrospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 24. The method according to claim 18, wherein the compound is 5-aminospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 25. The method according to claim 18, wherein the compound is 5-methylaminospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 26. A method of managing peptic ulcer in a patient which comprises administering to said patient a compound of the formula ##STR26## wherein R.sup.1' is di-C.sub.1-4 alkylamino, or a pharmaceutically acceptable salt thereof, said compound or salt being administered in an amount effective to manage peptic ulcer in said patient.
- 27. The method according to claim 26, wherein the compound is 5-dimethylaminospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 28. The method according to claim 26, wherein the compound is 5-diethylaminospiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
- 29. A method of managing peptic ulcer in a patient which comprises administering to said patient a compound of the formula ##STR27## wherein R.sup.1" is C.sub.2-6 alkanoyl, said compound being administered in an amount effective to manage peptic ulcer in said patient.
- 30. The method according to claim 29, wherein the compound is 5-acetylspiro[benzo[b]furan-2(3H),1'-cyclopropane]-3-one.
Priority Claims (5)
Number |
Date |
Country |
Kind |
52-159177 |
Dec 1977 |
JPX |
|
53-74700 |
Jun 1978 |
JPX |
|
53-136967 |
Nov 1978 |
JPX |
|
54-55082 |
May 1979 |
JPX |
|
54-80551 |
Jun 1979 |
JPX |
|
Parent Case Info
This application is a continuation-in-part of Ser. No. 968,520, filed Dec. 11, 1978 now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4105670 |
Noguchi et al. |
Aug 1978 |
|
Non-Patent Literature Citations (2)
Entry |
Okitsu et al., Heterocycles, vol. 6, No. 11 (1977), pp. 1877-1879. |
Donnelly et al., Chem. and Industry (1967), pp. 1402-1403. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
968520 |
Dec 1978 |
|